A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Stopped early · Phase 1

Conditions studied: Lymphoid Malignancies

In brief

The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.

Key facts

Study ID

NCT01013818

Run by

Human Genome Sciences Inc.

People needed

11

Starts

2009-10-01

Expected to finish

2011-10-01

Last updated by the study team

2013-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed relapsed/refractory lymphoid malignancies
• Previously treated with at least 2 therapeutic regimens
• ECOG performance < 2.
• Life expectancy of at least 3 months
• Adequate renal function
• Adequate hematologic status
• Adequate liver function
• Transfusion independent

You may not qualify if…

• Received other therapy (biological or drug) to treat cancer within 4 weeks prior to starting treatment with HGS1029 or who exhibit persistent clinical evidence of cancer treatment toxicity
• The use of systemic corticosteroids within 1 week of starting treatment with HGS1029
• Evidence of active bacterial, viral or fungal infection within 2 weeks before starting treatment with HGS1029
• Known HIV infection
• Positive for hepatitis B surface antigen or positive hepatitis C antibody
• Grade 2 or greater neuropathy
• Pregnant female or nursing mother
• Males or females who do not agree to use effective contraception during the study and through at least 30 days after the last dose of HGS1029

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Oxford Cancer and Haematology Centre — Headington, Oxford, United Kingdom
• The Institute of Cancer Research — Belmont, Sutton, Surrey, United Kingdom
• Cancer Research UK Centre — Southampton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.